In a filing with the US Securities and Exchange Commission (SEC), Californian biotech Alumis has revealed it aims to raise around $300 million in its upcoming initial public offering (IPO). 25 June 2024
CNS disorder specialist Intra-Cellular Therapies has announced positive topline results from Study 502, evaluating its depression candidate lumateperone. 19 June 2024
Elion Therapeutics, a biotechnology company focusing on invasive fungal infections, has announced the successful closing of an $81 million series B funding roun 17 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.